Drug Profile
AM 461
Alternative Names: AM461Latest Information Update: 16 Mar 2016
Price :
$50
*
At a glance
- Originator Amira Pharmaceuticals
- Developer Panmira Pharmaceuticals
- Class Anti-inflammatories; Antiallergics; Small molecules
- Mechanism of Action Prostaglandin D2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hypersensitivity; Inflammation
Most Recent Events
- 16 Mar 2016 No recent reports on development identified - Phase-I for Hypersensitivity in USA (PO)
- 16 Mar 2016 No recent reports on development identified - Phase-I for Inflammation in USA (PO)
- 07 Sep 2011 Amira Pharmaceuticals has been acquired by Bristol-Myers Squibb